Lurbinectedin for the treatment of small cell lung cancer

Li, L.; Zou, Changpeng; Dong, Shaowei; Wu, Zhidan; Ashby, Charles R.; Chen, Z.-S.; Qiu, Chao

doi:10.1358/dot.2021.57.6.3294559

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 As a proinflammatory cytokine, MIF promotes endothelial dysfunction and leads to enhanced BBB permeability. 11 Prior research has shown that an MIF antagonist plays a neuroprotective role in the pathology of stroke 12 and that increased MIF production can expand the neuroinflammatory process and amyloid βmediated neurotoxicity in Alzheimer's disease, which is associated with cognitive decline. 13,14 MIF is also associated with chronic vascular dysfunction and neurodegeneration pathology, 15 are increased in CSVD-CI patients as compared to CSVD-CN ones and are closely correlated with impaired executive function.…”

Section: ■ Introductionmentioning

confidence: 99%

Macrophage Migration Inhibitory Factor as a Potential Plasma Biomarker of Cognitive Impairment in Cerebral Small Vessel Disease

Shi,

Deng,

Mao

et al. 2024

ACS Omega

View full text Add to dashboard Cite

As the pathogenesis of cerebral small vessel disease with cognitive impairment (CSVD-CI) remains unclear, identifying effective biomarkers can contribute to the clinical management of CSVD-CI. This study recruited 54 healthy controls (HCs), 60 CSVD-CI patients, and 57 CSVD cognitively normal (CSVD-CN) patients. All participants underwent neuropsychological assessments and multimodal magnetic resonance imaging. Macrophage migration inhibitory factors (MIFs) were assessed in plasma. The least absolute shrinkage and selection operator model was used to determine a composite marker. Compared with HCs or CSVD-CN patients, CSVD-CI patients had significantly increased plasma MIF levels. In CSVD-CI patients, plasma MIF levels were significantly correlated with multiple cognitive assessment scores, plasma levels of blood−brain barrier (BBB)related indices, white matter hyperintensity Fazekas scores, and the mean amplitude of low-frequency fluctuation in the right superior temporal gyrus. Higher plasma MIF levels were significantly associated with worse global cognition and information processing speed in CSVD-CI patients. The composite marker (including plasma MIF) distinguished CSVD-CI patients from CSVD-CN and HCs with >80% accuracy. Meta-analysis indicated that blood MIF levels were significantly increased in CSVD-CI patients. In conclusion, plasma MIF is a potential biomarker for early identification of CSVD-CI. Plasma MIF may play a role in cognitive decline in CSVD through BBB dysfunction and changes in white matter hyperintensity and brain activity.

show abstract